Rational Use of Antibiotics: Strategies to Combat Antimicrobial Resistance in Treatment Guidelines and Hospital Policy

Antimicrobial resistance is one of the most critical challenges facing modern medicine. The indiscriminate use of antibiotics has accelerated the emergence of resistant bacteria, complicating the treatment of common infections and increasing the risk of severe complications. In this context, the rational use of antibiotics becomes an essential strategy to control this growing threat.

Deepening the Rational Use of Antibiotics

The rational use of antibiotics involves appropriate prescribing based on updated treatment guidelines and scientific evidence. A recent study on the pharmacokinetics of linezolid highlights the importance of adjusting doses in special populations to avoid subtherapeutic or toxic concentrations, which can contribute to antimicrobial resistance.

Moreover, the COVID-19 pandemic has exacerbated the problem of antimicrobial resistance. An analysis of bacterial and fungal superinfections in COVID-19 patients in Iran showed an increase in difficult-to-treat infections, underscoring the need for precise management in the post-pandemic crisis.

The combination of antibiotics has also been explored as a strategy to combat resistant strains. A study on in vitro antibiotic combinations against multidrug-resistant Klebsiella pneumoniae suggests that certain combinations may be effective, which could be a promising avenue for treating resistant infections.

Conclusions

Controlling antimicrobial resistance requires a multifaceted approach that includes the implementation of effective hospital policies, ongoing education for healthcare professionals, and continuous research into new therapies. Collaboration among physicians, pharmacists, and other healthcare professionals is crucial for developing effective strategies for the rational use of antibiotics.

In conclusion, antimicrobial resistance is a complex problem that demands immediate and sustained attention. By applying evidence-based treatment guidelines and promoting rational use policies for antibiotics, we can mitigate the impact of this global threat.

Referencias

• [1] Linezolid pharmacokinetics: a systematic review for the best clinical practice.
• [2] Respiratory Bacterial and Fungal Superinfections During the Third Surge of the COVID-19 Pandemic in Iran.
• [3] In Vitro antibiotic combinations of Colistin, Meropenem, Amikacin, and Amoxicillin/clavulanate against multidrug-resistant Klebsiella pneumonia isolated from patients with ventilator-associated pneumonia.

Created 13/1/2025